About FDA
Risk Communication Reports
New: FDA conducted a two-phase focus group study to develop a series of short, tagline messages that aim to provide consumers with the context they may need to have a better understanding of more complicated risk benefit information, and therefore enable better prescription drug decisions.
FDA and FDA's Advisory Committee for Risk Communication show our strategic planning for risk communication, and how to incorporate and build on risk communication related research.
Communicating Risks and Benefits: An Evidence-Based User's Guide
 |
Effective risk communication is essential to the well-being of any organization and those people who depend on it. Ineffective communication can cost lives, money, and reputations. Communicating Risks and Benefits: An Evidence-Based User's Guide provides the scientific foundations for effective communication. |
Strategic Plan for Risk Communication
The purpose of this document is to describe the U.S. Food and Drug Administration’s strategy for improving how the agency communicates about regulated products. The strategy is intended to guide program development and research planning in a dynamic environment where rapidly evolving technologies enable patients and consumers to become increasingly involved in managing their health and well-being. We define three key areas—science, capacity, and policy—in which strategic actions can help improve how we communicate about the risks and benefits of regulated products, as well as how we oversee communications produced by regulated entities.
